ArticleBMC infectious diseases2025
The natural history of anal cancer-associated human papillomavirus infection among cisgender men and transgender women who have sex with men in an acute HIV cohort in Thailand.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evolutionary Dynamics of Human Papillomavirus in Thailand: Immunoinformatic Design of a Synergistic L1/L2 Vaccine Candidate.Pharmaceuticals (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
introductionAnal cancer-associated human papillomavirus (caHPV) infection is the leading cause of anal cancer. This study describes human papillomavirus (HPV) progression among participants with acute HIV acquisition.
methodCisgender men and transgender women initiating antiretroviral therapy during acute HIV acquisition (Fiebig 1–5) underwent anal HPV testing at a sexual health clinic in Bangkok from May 2017 to June 2020. Demographic, sexual history, and laboratory data were collected at HIV diagnosis. Two-state Markov models were created to estimate probabilities and durations of HPV 16, 18/45, other caHPV, and any caHPV. Multivariate analyses were performed by adjusting for age and baseline CD4 count.
resultsA total of 94 participants (median age 26 years) were enrolled. Among 92 participants with valid baseline HPV results, 15.2% had HPV 16, 15.2% had HPV 18/45, 39.1% had other caHPV, and 67.4% had any caHPV at baseline. Over 225.9 person-years (PY), incidence rates were 18.0, 13.9, 44.1, and 82.5 per 100 PY, respectively. Clearance rates were 78.9, 102.9, 93.8, and 56.4 per 100 PY, respectively. Within 2 years of HIV, probabilities of caHPV acquisition were 0.42 for HPV 16, 0.37 for HPV 18/45, 0.82 for other caHPV, and 0.96 for any caHPV. Probabilities of caHPV clearance were 0.91, 0.97, 0.97, and 0.89, respectively. Having ≥ 6 lifetime sexual partners was associated with higher HPV 16 incidence compared to fewer partners (aHR 4.80, 95% CI 1.08–21.37), after adjusting for age and baseline CD4 count.
conclusionCancer-associated HPV acquisition remains high after acute HIV acquisition and initiation of antiretroviral therapy. Ongoing sexual health consultation, HPV vaccination, and anal cancer screening are necessary for people living with HIV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.